Alnylam Pharmaceuticals (NASDAQ: ALNY) Q2 2026 Earnings Preview for Thursday July 30, 2026 Before Market Open; Analyst Focus Areas Include the New ALN-6222 Investigational Subcutaneous siRNA Obesity Phase 1 Trial (NCT07624071, First-in-Human Single-Ascending-Dose Design Enrolling 88 Adults With BMI 30-40 kg/m² Through December 2027 at Mount Royal, Canada), the ALN-2232 Phase 1 Weight-Management Program (Phase 1 Readout Expected Second Half of 2026), the Alnylam-PeptiDream Peptide-siRNA Conjugate Extrahepatic Delivery Platform Milestone Announced December 2025, and the Broader Alnylam 2030 Strategy Launch Positioning Beyond the Amvuttra (Vutrisiran) Transthyretin Amyloidosis Franchise
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open. Analyst focus areas include the new ALN-6222 investigational subcutaneous siRNA obesity Phase 1 trial (NCT07624071, first-in-human single-ascending-dose randomized double-blind placebo-controlled design enrolling approximately 88 adults with BMI 30 to less than 40 kg/m² and HbA1c below 6.5% at a single site in Mount Royal, Canada through December 2027; molecular target of ALN-6222 has not been publicly disclosed). Also under focus: the Phase 1 ALN-2232 program (Alnylam's second obesity-track siRNA, with a Phase 1 readout expected in the second half of 2026), the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025 (demonstrating peptide-ligand-mediated targeted siRNA delivery to specific extrahepatic tissues), and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra (vutrisiran) transthyretin amyloidosis franchise. Alnylam's obesity pipeline is programmed against inhibin subunit beta E (INHBE) in liver and activin receptor type 1C (ACVR1C) in adipose tissue, both nucleic-acid modality targets that are distinct from GLP-1 agonism.